{"nctId":"NCT02065570","briefTitle":"Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease","startDateStruct":{"date":"2014-05-01","type":"ACTUAL"},"conditions":["Crohn's Disease"],"count":514,"armGroups":[{"label":"Induction: Standard Induction Dose","type":"EXPERIMENTAL","interventionNames":["Drug: Adalimumab","Drug: Placebo"]},{"label":"Induction: Higher Induction Dose","type":"EXPERIMENTAL","interventionNames":["Drug: Adalimumab"]},{"label":"Maintenance: Clinically Adjusted (CA) Regimen","type":"EXPERIMENTAL","interventionNames":["Drug: Adalimumab"]},{"label":"Maintenance: Therapeutic Drug Monitoring (TDM) Regimen","type":"EXPERIMENTAL","interventionNames":["Drug: Adalimumab"]}],"interventions":[{"name":"Adalimumab","otherNames":["Humira"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of Crohn's disease (CD) for at least 90 days, confirmed by endoscopy during the Screening Period.\n* Active CD with a Crohn's Disease Activity Index (CDAI) despite treatment with oral corticosteroids and/or immunosuppressants.\n* Mucosal ulceration on endoscopy.\n\nExclusion Criteria:\n\n* Subject with ulcerative colitis or indeterminate colitis.\n* Subject who has had surgical bowel resections in the past 6 months or is planning resection.\n* Subjects with an ostomy or ileoanal pouch.\n* Subject with symptomatic bowel stricture or abdominal or peri-anal abcess.\n* Subject who has short bowel syndrome.\n* Chronic recurring infections or active Tuberculosis (TB).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Achieved Clinical Remission at Week 4","description":"Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \\< 150, and very severe disease is defined as CDAI \\> 450.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.7","spread":null},{"groupId":"OG001","value":"43.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Endoscopic Response at Week 12","description":"Endoscopic response was scored using the Simplified Endoscopic Score for Crohn's Disease (SES-CD). The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \\[none\\] to 3 \\[very large\\]; ulcerated surface ranging from 0 \\[none\\] to 3 \\[\\>30%\\]; affected surface ranging from 0 \\[none\\] to 3 \\[\\>75%\\], and narrowing ranging from 0 \\[none\\] to 3 \\[cannot be passed\\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic response was defined as SES-CD total score \\> 50% from Baseline (or for a Baseline SES-CD of 4, at least a 2 point reduction from Baseline) at Week 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null},{"groupId":"OG001","value":"42.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"Adverse event (AE): any untoward medical occurrence that does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. Serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. TEAEs: any event that began or worsened in severity after the first dose of study drug in the induction or maintenance study. Events with unknown severity were counted as severe. Events with unknown relationship to study drug were counted as drug-related.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"185","spread":null},{"groupId":"OG002","value":"77","spread":null},{"groupId":"OG003","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"29","spread":null},{"groupId":"OG003","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Clinical Remission (Per CDAI) at Both Weeks 4 and 12","description":"CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \\< 150, and very severe disease is defined as CDAI \\> 450.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null},{"groupId":"OG001","value":"39.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve Clinical Response at Week 4 and Endoscopic Response at Week 12","description":"Clinical response was scored using CDAI, which assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \\< 150, and very severe disease is defined as CDAI \\> 450. Clinical response was defined as a decrease in CDAI â‰¥ 70 points from Baseline.\n\nEndoscopic response was scored using the SES-CD, which evaluates 4 endoscopic variables (ulcer size ranging from 0 \\[none\\] to 3 \\[very large\\]; ulcerated surface ranging from 0 \\[none\\] to 3 \\[\\>30%\\]; affected surface ranging from 0 \\[none\\] to 3 \\[\\>75%\\], and narrowing ranging from 0 \\[none\\] to 3 \\[cannot be passed\\]) in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic response was defined as SES-CD total score \\>50% from Baseline (or for Baseline SES-CD of 4, at least a 2-point reduction from Baseline) at Week 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":null},{"groupId":"OG001","value":"22.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Remission at Week 12","description":"Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \\< 150, and very severe disease is defined as CDAI \\> 450.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.5","spread":null},{"groupId":"OG001","value":"62.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission at Week 12 Among Participants Taking Corticosteroids at Baseline","description":"Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \\< 150, and very severe disease is defined as CDAI \\> 450.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":null},{"groupId":"OG001","value":"52.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Endoscopic Remission at Week 12","description":"Endoscopic remission was scored using the SES-CD.The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \\[none\\] to 3 \\[very large\\]; ulcerated surface ranging from 0 \\[none\\] to 3 \\[\\>30%\\]; affected surface ranging from 0 \\[none\\] to 3 \\[\\>75%\\], and narrowing ranging from 0 \\[none\\] to 3 \\[cannot be passed\\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic remission was defined as SES-CD â‰¤ 4 and at least a 2-point reduction versus baseline and no subscore greater than 1 in any individual variable.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":null},{"groupId":"OG001","value":"28.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fecal Calprotectin Level at Week 4","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1045.7","spread":"1648.51"},{"groupId":"OG001","value":"-1157.0","spread":"2000.69"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 Âµg/g at Week 4","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"32.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 Âµg/g at Week 4","description":"Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \\< 150, and very severe disease is defined as CDAI \\> 450.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"14.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 Âµg/g and Endoscopic Remission at Week 12","description":"Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \\< 150, and very severe disease is defined as CDAI \\> 450.\n\nEndoscopic remission was scored using the SES-CD.The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \\[none\\] to 3 \\[very large\\]; ulcerated surface ranging from 0 \\[none\\] to 3 \\[\\>30%\\]; affected surface ranging from 0 \\[none\\] to 3 \\[\\>75%\\], and narrowing ranging from 0 \\[none\\] to 3 \\[cannot be passed\\]) in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic remission was defined as SES-CD â‰¤ 4 and at least a 2-point reduction versus baseline and no subscore greater than 1 in any individual variable.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null},{"groupId":"OG001","value":"11.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved an SES-CD â‰¤ 2 at Week 12","description":"The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \\[none\\] to 3 \\[very large\\]; ulcerated surface ranging from 0 \\[none\\] to 3 \\[\\>30%\\]; affected surface ranging from 0 \\[none\\] to 3 \\[\\>75%\\], and narrowing ranging from 0 \\[none\\] to 3 \\[cannot be passed\\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"20.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Response at Week 4","description":"Clinical response was scored using CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \\< 150, and very severe disease is defined as CDAI \\> 450. Clinical response was defined as a decrease in CDAI â‰¥ 70 points from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.9","spread":null},{"groupId":"OG001","value":"74.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Response at Week 12","description":"Clinical response was scored using CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \\< 150, and very severe disease is defined as CDAI \\> 450. Clinical response was defined as a decrease in CDAI â‰¥ 70 points from Baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":null},{"groupId":"OG001","value":"83.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom Domain at Week 4","description":"The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score â‰¥ 8.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null},{"groupId":"OG001","value":"74.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 12","description":"The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score â‰¥ 8.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":null},{"groupId":"OG001","value":"76.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 12","description":"The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The IBDQ Fatigue item score range is from 1 (severe problem) to 7 (normal health). Response is defined as an increase of IBDQ Fatigue item score â‰¥ 1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":null},{"groupId":"OG001","value":"76.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":206},"commonTop":["CROHN'S DISEASE","NASOPHARYNGITIS","HEADACHE","ARTHRALGIA","NAUSEA"]}}}